Animal Growth and Development Laboratory, Department of Animal Science, University of Minnesota, 1354 Eckles Ave., St. Paul, MN 55108, USA.
Domest Anim Endocrinol. 2011 May;40(4):197-204. doi: 10.1016/j.domaniend.2011.01.001. Epub 2011 Feb 11.
Insulin-like growth factor binding protein-3 (IGFBP-3) suppresses proliferation of numerous cell types, including myogenic cells, via both insulin-like growth factor (IGF)-dependent and IGF-independent mechanisms; however, the mechanism of IGF-independent suppression of proliferation is not clearly defined. In nonmuscle cells, binding of IGFBP-3 to the low-density lipoprotein receptor-related protein-1 (LRP-1)/activated α(2)M receptor is reportedly required for IGFBP-3 to inhibit proliferation. These findings suggest that binding to this receptor also may be required for IGFBP-3 to suppress proliferation of cultured myogenic cells. To investigate the role of the LRP-1 receptor in suppression of myogenic cell proliferation by IGFBP-3, we have examined the effect of receptor-associated protein, an LRP-1 receptor antagonist, on recombinant porcine (rp)IGFBP-3 inhibition of L6 myogenic cell proliferation. Treatment with receptor-associated protein results in a 37% decrease (P < 0.05) in the ability of rpIGFBP-3 to inhibit L6-cell proliferation. In L6 cells subjected to LRP-1 small interfering RNA treatment for 48 h (LRP-1 silenced), LRP-1 mRNA levels were reduced by greater than 80% compared with control cultures treated with nonsense small interfering RNA (mock silenced). In addition, the 85-kDa transmembrane subunit of LRP-1 was undetectable in Western immunoblots of total protein lysates from LRP-1-silenced cells. Even though LRP-1 mRNA and protein levels were dramatically reduced in LRP-1-silenced L6 cells compared with mock-silenced controls, rpIGFPB-3 suppressed proliferation rate to the same extent in both LRP-1-silenced and mock-silenced cultures. Our results strongly suggest that, in contrast to data obtained for nonmuscle cell lines, the LRP-1 receptor is not required for IGFBP-3 to suppress proliferation of L6 myogenic cells.
胰岛素样生长因子结合蛋白 3(IGFBP-3)通过胰岛素样生长因子(IGF)依赖和 IGF 非依赖机制抑制多种细胞类型的增殖,包括成肌细胞;然而,IGF 非依赖性抑制增殖的机制尚不清楚。在非肌肉细胞中,据报道,IGFBP-3 与低密度脂蛋白受体相关蛋白-1(LRP-1)/激活的 α2M 受体结合是 IGFBP-3 抑制增殖所必需的。这些发现表明,与该受体结合也可能是 IGFBP-3 抑制培养的成肌细胞增殖所必需的。为了研究 LRP-1 受体在 IGFBP-3 抑制成肌细胞增殖中的作用,我们研究了受体相关蛋白(LRP-1 受体拮抗剂)对重组猪(rp)IGFBP-3 抑制 L6 成肌细胞增殖的影响。用受体相关蛋白处理导致 rpIGFBP-3 抑制 L6 细胞增殖的能力降低 37%(P < 0.05)。在接受 LRP-1 小干扰 RNA 处理 48 小时的 L6 细胞(LRP-1 沉默)中,与用无意义小干扰 RNA(mock 沉默)处理的对照培养物相比,LRP-1 mRNA 水平降低了 80%以上。此外,LRP-1 沉默的 L6 细胞的总蛋白裂解物的 Western 免疫印迹中未检测到 LRP-1 的 85 kDa 跨膜亚基。尽管与 mock 沉默对照相比,LRP-1 沉默的 L6 细胞中的 LRP-1 mRNA 和蛋白水平显着降低,但 rpIGFPB-3 抑制增殖率在 LRP-1 沉默和 mock 沉默的培养物中相同。我们的结果强烈表明,与非肌肉细胞系获得的数据相反,LRP-1 受体不是 IGFBP-3 抑制 L6 成肌细胞增殖所必需的。